Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Phase II Trial of Combined Modality Treatment in Primary Central Nervous System Lymphoma

This study has been completed.
Sponsor:
Information provided by:
International Extranodal Lymphoma Study Group (IELSG)
ClinicalTrials.gov Identifier:
NCT00210314
First received: September 13, 2005
Last updated: July 22, 2009
Last verified: July 2009